NEW YORK – Drawing on its longstanding partnership with Becton Dickinson, Babson Diagnostics is aiming to further expand use of its US Food and Drug Administration-cleared blood collection system ...

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

The company was in violation of the stock exchange's requirements for the minimum bid price and the market value of listed securities.

The prognostic test stratifies hospitalized women with hypertensive disorders of pregnancy into low- and high-risk categories for developing severe preeclampsia.

The firm's Q4 2024 overall revenues were up 7 percent and full-year 2024 revenues were up 5 percent. Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith ...

Gravity Diagnostics provides testing for toxicology, pharmacogenetics, infectious and upper respiratory diseases, blood diagnostics, and COVID-19.

Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

The diagnostics startup is developing a testing platform that uses digital imaging and signal processing for pathogen identification and susceptibility determination.

The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.